Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic|Melanoma|Non Small Cell Lung Cancer (NSCLC)|Breast Cancer|Pancreatic Cancer
Interventions: RADIATION: Radiotherapy|DRUG: MEDI4736|DRUG: Tremelimumab
Sponsor: Abramson Cancer Center at Penn Medicine